Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
1372- Ash,    Withaferin-A Induces Apoptosis in Osteosarcoma U2OS Cell Line via Generation of ROS and Disruption of Mitochondrial Membrane Potential
- in-vitro, OS, U2OS
Apoptosis↑, ROS↑, MMP↓, Casp3↑,
1373- Ash,    Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells
- in-vitro, Kidney, Caki-1
ER Stress↑, p‑eIF2α↑, XBP-1↑, GRP78/BiP↑, CHOP/DDIT3↑, eff↓,
1355- Ash,    Withaferin A-Induced Apoptosis in Human Breast Cancer Cells Is Mediated by Reactive Oxygen Species
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, HMEC
eff↑, mt-ROS↑, mitResp↓, OXPHOS↓, compIII↑, BAX↑, Bak↑, other↓, ATP∅, *ROS∅,
1356- Ash,    Withaferin A induces apoptosis by ROS-dependent mitochondrial dysfunction in human colorectal cancer cells
- in-vitro, CRC, HCT116
ROS↑, TumCCA↑, MMP↓, TumCG↓, Apoptosis↑, JNK↝,
1357- Ash,    Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vitro, GBM, GL26
TumCP↓, TumCCA↑, Akt↓, mTOR↓, p70S6↓, p85S6K↓, AMPKα↑, TSC2↑, HSP70/HSPA5↑, HO-1↑, HSF1↓, Apoptosis↑, ROS↑, eff↓,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1359- Ash,    Withaferin A Induces ROS-Mediated Paraptosis in Human Breast Cancer Cell-Lines MCF-7 and MDA-MB-231
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
MMP↓, Alix/AIP‑1↓, ROS↑, Paraptosis↑, ER Stress↝,
1360- Ash,  immuno,    Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
- in-vitro, Lung, H1650 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
PD-L1↑, eff↓, ROS↑, ER Stress↑, Apoptosis↑, BAX↑, Bak↑, BAD↑, Bcl-2↓, XIAP↓, survivin↓, cl‑PARP↑, CHOP/DDIT3↑, p‑eIF2α↑, ICD↑, eff↑,
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
1364- Ash,    Withaferin a Triggers Apoptosis and DNA Damage in Bladder Cancer J82 Cells through Oxidative Stress
- in-vitro, Bladder, J82
cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, ROS↑, MMP↓, DNAdam↑, eff↓,
1365- Ash,    Withaferin A Induces Oxidative Stress-Mediated Apoptosis and DNA Damage in Oral Cancer Cells
- in-vitro, Oral, Ca9-22 - in-vitro, Oral, CAL27
ROS↑, *toxicity↓, Apoptosis↑, TumCCA↑, MMP↓, p‑γH2AX↑, DNAdam↑, eff↓,
1367- Ash,    An anti-cancerous protein fraction from Withania somnifera induces ROS-dependent mitochondria-mediated apoptosis in human MDA-MB-231 breast cancer cells
- in-vitro, BC, MDA-MB-231
Apoptosis↑, ROS↑, Bax:Bcl2↑, MMP↓, Casp3↑, TumCCA↑,
1181- Ash,    Withaferin A inhibits Epithelial to Mesenchymal Transition in Non-Small Cell Lung Cancer Cells
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
TumCMig↓, TumCI↓, EMT↓, p‑SMAD2↓, p‑SMAD3↓, p‑NF-kB↓,
1180- Ash,    Withaferin A Inhibits Liver Cancer Tumorigenesis by Suppressing Aerobic Glycolysis through the p53/IDH1/HIF-1α Signaling Axis
- in-vitro, Liver, HepG2
IDH1↑, Glycolysis↓, P53↑, Hif1a↓,
1179- Ash,    Withaferin-A Inhibits Colon Cancer Cell Growth by Blocking STAT3 Transcriptional Activity
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCP↓, TumCMig↓, STAT3↓, TumVol↓, TumW↓,
1178- Ash,    Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
*VEGF↓, *angioG↓, *ascitic↓, *Sp1/3/4↓,
1177- Ash,    Withaferin A downregulates COX-2/NF-κB signaling and modulates MMP-2/9 in experimental endometriosis
- in-vivo, EC, NA
TumVol↓, MMP2↓, MMP9↓, NF-kB↓, COX2/PTGS2↓, NO↓, IL1β↓, IL6↓,
1176- Ash,    Metabolic Alterations in Mammary Cancer Prevention by Withaferin A in a Clinically Relevant Mouse Model
- in-vivo, NA, NA
TumVol↓, Apoptosis↑, Glycolysis↓, PKM2↓, PGK1↓, ALDOAiso2↓,
1174- Ash,    Withaferin A Suppresses Estrogen Receptor-α Expression in Human Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vivo, BC, MDA-MB-231 - in-vitro, BC, T47D
p‑P53↑, Apoptosis↑, ERα/ESR1↓,
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
1172- Ash,    Withaferin A Inhibits Fatty Acid Synthesis in Rat Mammary Tumors
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
FASN↓, ACLY↓, ACC1↓, CPT1A↓, SREBP1/SREBF1↓,
1433- Ash,  SFN,    A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
eff↑, Bcl-2↓, BAX↑, tumCV↓, DNMT1↓, DNMT3A↓, HDAC↓,
2001- Ash,    Withania somnifera: from prevention to treatment of cancer
- Review, Var, NA
toxicity↓, TumW↓, Dose?, eff↝, Ki-67↓, survivin↓, XIAP↓, PERK↑, p‑RSK↑, CHOP/DDIT3↑, DR5↑, Dose↝, BG↓, DNMTs↓,
2002- Ash,    Ancient medicine, modern use: Withania somnifera and its potential role in integrative oncology
- Review, Var, NA
antiOx↑, Inflam↓, TumCP↓, OS↑, RadioS↑, radioP↑, chemoP↑,
2003- Ash,    Withaferin A Induces Cell Death Selectively in Androgen-Independent Prostate Cancer Cells but Not in Normal Fibroblast Cells
- in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, Nor, TIG-1 - in-vitro, PC, LNCaP
TumCD↑, selectivity↑, cFos↑, ROS↑, *ROS∅, HSP70/HSPA5↑, Apoptosis↑, ER Stress↑, TumCCA↑,
4303- Ash,    Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review
- Review, AD, NA
*neuroP↑, *Sleep↑, *Inflam↓, *cardioP↑, *cognitive↑, *Aβ↓, *TNF-α↓, *IL1β↓, *IL6↓, *MCP1/CCL2↓, *lipid-P↓, *tau↓, *ROS↓, *BBB↑, *AChE↓, *GSH↑, *GSTs↑, *GSR↑, *GPx↑, *SOD↑, *Catalase↑, ChemoSen↑, *Strength↑,
5169- Ash,    The Tumor Inhibitor and Antiangiogenic Agent Withaferin A Targets the Intermediate Filament Protein Vimentin
- in-vitro, BC, MCF7
AntiTum↑, angioG↓, Vim↓,
5170- Ash,    Withaferin A inhibits NF-kappaB activation by targeting cysteine 179 in IKKβ
- Review, Var, NA
NF-kB↓, Inflam↓, IKKα↓,
5171- Ash,    The tumor proteasome is a primary target for the natural anticancer compound Withaferin A isolated from "Indian winter cherry"
- vitro+vivo, Pca, LNCaP - vitro+vivo, Pca, PC3
Proteasome↓, BAX↑, p27/CDKN1B↑, AR↓, TumCG↓,
5172- Ash,    Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells
Akt↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓, Snail↓, Slug↓, β-catenin/ZEB1↓, Vim↓, angioG↓,
5173- Ash,  2DG,    Withaferin A inhibits lysosomal activity to block autophagic flux and induces apoptosis via energetic impairment in breast cancer cells
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468 - in-vitro, BC, T47D
autoF↓, lysosome↓, TumAuto↑, p‑LDH↓, ATP↓, AMPK↑, eff↑, TumCG↓, CTSD↓, CTSB↓, CTSL↑, cl‑PARP1↑, LDHA↓, TCA↓,
5174- Ash,    Withaferin A is a potent inhibitor of angiogenesis
- in-vitro, Nor, HUVECs
Inflam↓, *TumCP↓, cycD1/CCND1↓, NF-kB↓, angioG↓,
5175- Ash,    Withaferin A Induces Proteasome Inhibition, Endoplasmic Reticulum Stress, the Heat Shock Response and Acquisition of Thermotolerance
- in-vitro, Cerv, CCL-102
Inflam↓, AntiTum↑, Proteasome↓, ER Stress↑, HSPs↑, GRP94↑, Akt↑, eff↑, HSP70/HSPA5↑,
4660- Ash,    Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells
- in-vitro, Ovarian, NA
CSCs↓, TumCG↓, TumMeta↓, CD44↓, CD34↓, OCT4↓, NOTCH1↓, HEY1↓,
4677- Ash,    Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
- vitro+vivo, Ovarian, NA
CSCs↓, Securin↓, ALDH1A1↓,
4678- Ash,    Identification of Withaferin A as a Potential Candidate for Anti-Cancer Therapy in Non-Small Cell Lung Cancer
- vitro+vivo, NSCLC, H1975
ROS↑, AntiTum↑, CSCs↓, mTOR↓, STAT3↓, ChemoSen↑, Keap1↑, NRF2↓,
4679- Ash,    Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell
- in-vitro, NA, NA
CSCs↓,
5384- AsP,  MEL,    Synergistic Anticancer Effect of Melatonin and Ascorbyl Palmitate Nanoformulation: A Promising Combination for Cancer Therapy
- in-vivo, Var, NA
AntiCan↑, TumCG↓, Apoptosis↑, DNAdam↑, TumCCA↑, IL6↓, STAT3↓, TumCP↓, Ki-67↓, TumCI↓, TumMeta↓, MMP9↓, eff↑, *Catalase↑, *SOD↑, *GSH↑, *MDA↓, *NO↓, *antiOx↑, *hepatoP↑, *RenoP↑,
5385- AsP,  GoldNP,  GEM,    Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery
- in-vitro, BC, NA
ROS↑, Fenton↑, BioAv↑, EPR↑,
5388- AsP,    Capacity of Ascorbyl Palmitate to Produce the Ascorbyl Radical in Vitro: an Electron Spin Resonance Investigation
- in-vitro, Nor, NA
other↑,
5389- AsP,  Tras,    ASCORBYL PALMITATE ENHANCES ANTI-PROLIFERATIVE EFFECT OF TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER CELLS
tumCV↓, eff↑, P53↑, BAX↑, Casp3↑, Casp8↑, Bcl-2↓, Apoptosis↑, p‑p38↓, ERK↓, PI3K↓,
5391- AsP,    Research Progress of Ascorbyl Palmitate in Drug Delivery and Cancer Therapy
- Review, Var, NA
*antiOx↑, toxicity↓,
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
1146- AsP,    Potential use of nanoformulated ascorbyl palmitate as a promising anticancer agent: First comparative assessment between nano and free forms
- in-vivo, Nor, NA
TumCCA↑, Apoptosis↑, IL6↓, STAT3↓, angioG↓, TumMeta↓, VEGF↓, MMP9↓, SOD↑, Catalase↑, GSH↓, MDA↓, NO↓, *BioAv↑,
4814- ASTX,    Chemopreventive and therapeutic efficacy of astaxanthin against cancer: A comprehensive review
- Review, Var, NA
Apoptosis↑, EMT↓, AntiCan↑, *cardioP↑, *neuroP↑, TumCG↓, *antiOx↑, *Bacteria↓, *Imm↑, *hepatoP↑, *AntiDiabetic↑, ROS↓, *chemoPv↑,
4825- ASTX,    In vivo protective efficacy of astaxanthin against ionizing radiation-induced DNA damage
- in-vivo, Nor, NA
*DNAdam↓, *radioP↑,
4824- ASTX,  Rad,    Astaxanthin protects the radiation-induced lung injury in C57BL/6 female mice
- in-vivo, Nor, NA
*radioP↑, Inflam↓,
4823- ASTX,    Astaxanthin increases radiosensitivity in esophageal squamous cell carcinoma through inducing apoptosis and G2/M arrest
- in-vitro, ESCC, NA
RadioS↑, Apoptosis↑, TumCCA↑, Bcl-2↓, CycB/CCNB1↓, CDC2↓, BAX↑,

Showing Research Papers: 1001 to 1050 of 8263
Prev Page 21 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8263

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   GSH↓, 1,   HO-1↑, 1,   ICD↑, 1,   Keap1↑, 1,   MDA↓, 1,   NRF2↓, 2,   OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 15,   mt-ROS↑, 1,   SOD↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   ATP∅, 1,   BCR-ABL↓, 1,   CDC2↓, 1,   compIII↑, 1,   mitResp↓, 1,   MMP↓, 6,   Mortalin↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACC1↓, 1,   ACLY↓, 1,   ALDOAiso2↓, 1,   AMPK↑, 1,   CPT1A↓, 1,   FASN↓, 1,   Glycolysis↓, 2,   IDH1↑, 1,   p‑LDH↓, 1,   LDHA↓, 1,   PGK1↓, 1,   PKM2↓, 1,   SREBP1/SREBF1↓, 1,   TCA↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Akt↑, 1,   Apoptosis↑, 19,   BAD↑, 1,   Bak↑, 2,   BAX↑, 6,   Bax:Bcl2↑, 2,   Bcl-2↓, 4,   Casp3↑, 3,   cl‑Casp3↑, 2,   Casp8↑, 1,   cl‑Casp8↑, 1,   cl‑Casp9↑, 1,   DR5↑, 1,   Ferroptosis↑, 1,   HEY1↓, 1,   JNK↝, 1,   p27/CDKN1B↑, 1,   p‑p38↓, 1,   Paraptosis↑, 1,   Proteasome↓, 2,   p‑RSK↑, 1,   survivin↓, 2,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

AMPKα↑, 1,   p70S6↓, 1,   Sp1/3/4↓, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↓, 1,   other↑, 2,   tumCV↓, 2,   YMcells↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 3,   p‑eIF2α↑, 2,   ER Stress↑, 5,   ER Stress↝, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,   HSF1↓, 1,   HSP70/HSPA5↑, 3,   HSP90↓, 1,   HSPs↑, 1,   PERK↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

autoF↓, 1,   LC3B↑, 1,   lysosome↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

DNA-PK↑, 1,   DNAdam↑, 4,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   m-FAM72A↓, 1,   P53↑, 2,   p‑P53↑, 1,   cl‑PARP↑, 2,   cl‑PARP1↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   Securin↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD34↓, 1,   CD44↓, 1,   cFos↑, 1,   cMYB↓, 1,   CSCs↓, 5,   CTSB↓, 1,   CTSD↓, 1,   CTSL↑, 1,   EMT↓, 4,   ERK↓, 1,   HDAC↓, 1,   mTOR↓, 2,   NOTCH1↓, 1,   OCT4↓, 1,   p85S6K↓, 1,   PI3K↓, 1,   STAT3↓, 4,   TumCG↓, 8,  

Migration(tgid=13) ⓘ

Alix/AIP‑1↓, 1,   annexin II↓, 1,   F-actin↓, 1,   Ki-67↓, 2,   MMP2↓, 1,   MMP9↓, 3,   ROCK1↓, 1,   Slug↓, 1,   p‑SMAD2↓, 2,   p‑SMAD3↓, 1,   Snail↓, 1,   TGF-β↓, 1,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 8,   TumMeta↓, 4,   Vim↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   EGFR↓, 1,   EPR↑, 2,   Hif1a↓, 2,   NO↓, 2,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IKKα↓, 1,   IL1β↓, 1,   IL6↓, 3,   Inflam↓, 5,   NF-kB↓, 4,   p‑NF-kB↓, 1,   PD-L1↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 2,   ChemoSen↑, 7,   Dose?, 1,   Dose↝, 2,   eff↓, 6,   eff↑, 9,   eff↝, 1,   RadioS↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   BG↓, 1,   EGFR↓, 1,   ERα/ESR1↓, 1,   IL6↓, 3,   Ki-67↓, 2,   p‑LDH↓, 1,   PD-L1↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   AntiTum↑, 3,   chemoP↑, 1,   OS↑, 1,   radioP↑, 1,   toxicity↓, 2,   toxicity↝, 1,   TumVol↓, 3,   TumW↓, 2,  
Total Targets: 182

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 2,   GSR↑, 1,   GSTs↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 1,   ROS∅, 2,   SOD↑, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   NO↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   MCP1/CCL2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,   tau↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ascitic↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   cardioP↑, 2,   chemoPv↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   radioP↑, 2,   RenoP↑, 1,   Sleep↑, 1,   Strength↑, 1,   toxicity↓, 3,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 43

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page